Xenon Pharmaceuticals Inc (XENE)
Xenon Pharmaceuticals Inc. is a biotechnology company focused on developing innovative medicines for neurological and neurological-like disorders. It specializes in using its proprietary platform to identify and develop targeted therapies, with a strong focus on pain, epilepsy, and other neurological conditions. The company employs a deep understanding of ion channels and genetics to advance its pipeline of potential treatments.
Company News
Xenon Pharmaceuticals granted 24,200 share options to six new non-officer employees, with an exercise price of $30.54 per share, vesting over four years.
Longboard (LBPH) gains 14% as the FDA grants the Breakthrough Therapy designation to its investigational epilepsy treatment candidate, bexicaserin, for patients aged two years or older.
Within the last quarter, Xenon Pharmaceuticals (NASDAQ:XENE) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 0 4 0 0 0 Last 30D 0 1 0 0 0 1M Ago 0 2 0 0 0 2M Ago 0 0 0 0 0 3M Ago 0 1 0 0 0 According to 4 analyst offering 12-month price targets in the last 3 months, Xenon Pharmaceuticals has an average price target of $54.0 with a high of $63.00 and a low of $46.00. ...Full story available on Benzinga.com
Welcome to another installment of our monthly Rare Stock Picks article, where we highlight investment picks you may have missed. Explore more details here.
Xenon Pharmaceuticals shares fell early Monday after the company released new clinical-trial data on an experimental depression treatment.